AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Conjunctivitis, Allergic
Intervention: AGN-229666 (Drug); Vehicle to AGN-229666 (Drug); Olopatadine (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of
allergen-mediated conjunctivitis.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Primary outcome: Ocular Itching Score Using a 6-Point Scale
Secondary outcome: Conjunctival Hyperemia Score Using a 9-Point Scale
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Japanese patients living in Japan with a history of allergic conjunctivitis.
Exclusion Criteria:
- Presence of active eye infection (bacterial, viral, or fungal)
- History of an eye herpetic infection.
Locations and Contacts
Tokyo, Japan
Additional Information
Starting date: June 2014
Last updated: January 15, 2015
|
